<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Methods - Alzheimer's Disease Risk Calculator</title>
    <style>
                .navbar {
            overflow: hidden;
            background-color: #333;
            margin-bottom: 20px;
        }

        .navbar a {
            float: left;
            display: block;
            color: #f2f2f2;
            text-align: center;
            padding: 14px 16px;
            text-decoration: none;
        }

        .navbar a:hover {
            background-color: #ddd;
            color: black;
        }

        .navbar a.active {
            background-color: #0ea5e9;
            color: white;
        }

        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
            background: #000000;
            min-height: 100vh;
            padding: 20px;
            color: #e8e8e8;
            line-height: 1.7;
        }

        .container {
            max-width: 1000px;
            margin: 0 auto;
            background: #1a1a1a;
            border-radius: 12px;
            box-shadow: 0 8px 32px rgba(255, 255, 255, 0.1);
            overflow: hidden;
            border: 1px solid #333333;
        }

        .header {
            background: linear-gradient(135deg, #111111 0%, #222222 100%);
            color: #ffffff;
            padding: 40px 30px;
            text-align: center;
            border-bottom: 2px solid #333333;
        }

        .header h1 {
            font-size: 2.4rem;
            margin-bottom: 12px;
            font-weight: 700;
            letter-spacing: -0.5px;
        }

        .header p {
            opacity: 0.85;
            font-size: 1.1rem;
            font-weight: 400;
        }

        .content {
            padding: 40px;
            background: #1a1a1a;
        }

        .section {
            margin-bottom: 40px;
        }

        .section h2 {
            color: #ffffff;
            font-size: 1.8rem;
            margin-bottom: 20px;
            border-bottom: 2px solid #0ea5e9;
            padding-bottom: 12px;
            font-weight: 600;
        }

        .section h3 {
            color: #ffffff;
            font-size: 1.3rem;
            margin-bottom: 16px;
            margin-top: 24px;
            font-weight: 600;
        }

        .section h4 {
            color: #ffffff;
            font-size: 1.1rem;
            margin-bottom: 12px;
            margin-top: 20px;
            font-weight: 600;
        }

        .section p {
            color: #e8e8e8;
            margin-bottom: 16px;
            font-size: 1rem;
            line-height: 1.7;
        }

        .section ul {
            margin-left: 20px;
            margin-bottom: 16px;
        }

        .section li {
            color: #e8e8e8;
            margin-bottom: 8px;
            line-height: 1.6;
        }

        .highlight-box {
            background: #2a2a2a;
            border: 1px solid #404040;
            border-left: 4px solid #0ea5e9;
            border-radius: 8px;
            padding: 20px;
            margin: 20px 0;
        }

        .highlight-box h4 {
            color: #0ea5e9;
            margin-bottom: 12px;
        }

        .formula-box {
            background: #222222;
            border: 1px solid #444444;
            border-radius: 6px;
            padding: 16px;
            margin: 16px 0;
            font-family: 'Courier New', monospace;
            text-align: center;
            font-size: 1.1rem;
            color: #ffffff;
        }

        .data-table {
            width: 100%;
            border-collapse: collapse;
            margin: 20px 0;
            background: #2a2a2a;
            border-radius: 8px;
            overflow: hidden;
        }

        .data-table th {
            background: #333333;
            color: #ffffff;
            padding: 12px;
            text-align: left;
            font-weight: 600;
        }

        .data-table td {
            padding: 10px 12px;
            border-bottom: 1px solid #404040;
            color: #e8e8e8;
        }

        .data-table tr:last-child td {
            border-bottom: none;
        }

        .stats-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(200px, 1fr));
            gap: 20px;
            margin: 20px 0;
        }

        .stat-card {
            background: #2a2a2a;
            border: 1px solid #404040;
            border-radius: 8px;
            padding: 20px;
            text-align: center;
        }

        .stat-card h4 {
            color: #0ea5e9;
            margin-bottom: 8px;
            font-size: 0.9rem;
        }

        .stat-value {
            color: #ffffff;
            font-size: 1.4rem;
            font-weight: bold;
            margin-bottom: 4px;
        }

        .stat-description {
            color: #cccccc;
            font-size: 0.8rem;
        }

        .references {
            background: #1a1a1a;
            border-radius: 8px;
            padding: 20px;
            border: 1px solid #333333;
            margin-top: 20px;
        }

        .references h2 {
            color: #ffffff;
            font-size: 1.5rem;
            margin-bottom: 15px;
            border-bottom: 1px solid #0ea5e9;
            padding-bottom: 10px;
        }

        .references ol {
            list-style-type: decimal;
            margin-left: 20px;
            color: #e8e8e8;
        }

        .references li {
            margin-bottom: 10px;
            line-height: 1.6;
        }

        .references li a {
            color: #0ea5e9;
            text-decoration: none;
        }

        .references li a:hover {
            text-decoration: underline;
        }

        .back-link {
            display: inline-block;
            background: linear-gradient(135deg, #0ea5e9 0%, #0284c7 100%);
            color: white;
            text-decoration: none;
            padding: 12px 24px;
            border-radius: 6px;
            font-weight: 600;
            font-size: 14px;
            transition: all 0.3s ease;
            margin-top: 30px;
        }

        .back-link:hover {
            background: linear-gradient(135deg, #0284c7 0%, #0369a1 100%);
            transform: translateY(-1px);
            box-shadow: 0 4px 12px rgba(14, 165, 233, 0.3);
        }

        @media (max-width: 768px) {
            .container {
                margin: 10px;
            }
            
            .content {
                padding: 20px;
            }
            
            .header h1 {
                font-size: 1.8rem;
            }

            .stats-grid {
                grid-template-columns: 1fr;
            }
        }
    </style>
</head>
<body>
        <div class="navbar">
        <a href="index.html">Home</a>
        <a href="background.html">Background</a>
        <a href="methods.html" class="active">Methods</a>
        <a href="cases.html">Cases</a>
    </div>
    <div class="container">
        <div class="header">
            <h1>Methods</h1>
            <p>Alzheimer's Disease Risk Calculator Development</p>
        </div>

        <div class="content">
            <div class="section">
                <h2>Introduction</h2>
                <p>The following methods describe the development and validation of an Alzheimer's disease risk calculator based on plasma pTau 217/β-Amyloid 1-42 ratio biomarker testing. The primary dataset comprises 499 patients aged 52-93 years from a multi-site clinical validation study supporting FDA clearance (K242706) of the plasma ratio test.</p>
                
                <p>Study participants presented with cognitive decline symptoms across the spectrum from subjective cognitive decline to Alzheimer's disease dementia. Amyloid pathology status was confirmed using FDA-cleared amyloid PET tracers or cerebrospinal fluid amyloid ratio tests as reference standards. The risk calculator integrates validated likelihood ratios from biomarker testing with established epidemiological data to provide personalized risk estimates for clinical decision-making.</p>
                
                <p>The development process demonstrates the clinical performance characteristics of the plasma biomarker test, risk stratification across age groups and test results, and practical applications through representative clinical scenarios. The data support the clinical utility of plasma-based biomarker testing for Alzheimer's disease risk assessment in specialized care settings.</p>
            </div>

            <div class="section">
                <h2>Study Design and Data Sources</h2>
                
                <h3>Primary Data Source</h3>
                <p>The risk calculator was developed using clinical performance data from the FDA 510(k) premarket clearance submission (K242706) for the Lumipulse G pTau 217/β-Amyloid 1-42 Plasma Ratio test.<sup><a href="#ref-1">1</a>,<a href="#ref-2">2</a></sup> This submission contained validated clinical data from a prospective study of 499 patients aged 52-93 years presenting with cognitive decline symptoms across multiple specialized care settings.</p>

                <h3>Clinical Validation Dataset</h3>
                <div class="stats-grid">
                    <div class="stat-card">
                        <h4>Total Participants</h4>
                        <div class="stat-value">499</div>
                        <div class="stat-description">patients</div>
                    </div>
                    <div class="stat-card">
                        <h4>Age Range</h4>
                        <div class="stat-value">52-93</div>
                        <div class="stat-description">years (mean 72)</div>
                    </div>
                    <div class="stat-card">
                        <h4>Male Participants</h4>
                        <div class="stat-value">48.1%</div>
                        <div class="stat-description">(n=240)</div>
                    </div>
                    <div class="stat-card">
                        <h4>Amyloid Positive</h4>
                        <div class="stat-value">51.1%</div>
                        <div class="stat-description">(n=255)</div>
                    </div>
                </div>

                <p><strong>Diagnostic categories:</strong> Alzheimer's disease dementia (58.1%, n=290), mild cognitive impairment (30.9%, n=154), subjective cognitive decline (9.8%, n=49), and other cognitive diagnoses (1.2%, n=6)</p>

                <p><strong>Reference standard:</strong> Amyloid positivity confirmed by FDA-cleared amyloid PET tracers or FDA-cleared CSF amyloid ratio tests<sup><a href="#ref-3">3</a></sup></p>

                <p><strong>Study sites:</strong> Multi-site collaboration including Polaris-AD (AriBio), BioFINDER-2 (Skåne University Hospital), Bio-Hermes-001 (Global Alzheimer's Platform Foundation), and Wisconsin Registry for Alzheimer's Prevention</p>

                <h3>Supplementary Data Sources</h3>
                <p><strong>Epidemiological baseline risk data</strong> were derived from published population-based studies and meta-analyses providing age-stratified Alzheimer's disease incidence rates.<sup><a href="#ref-4">4</a></sup> <strong>APOE genotype risk modifiers</strong> were obtained from established genetic association studies with documented odds ratios for each genotype combination.<sup><a href="#ref-5">5</a></sup> <strong>Cognitive status progression rates</strong> were based on longitudinal cohort studies tracking conversion from normal cognition through mild cognitive impairment to dementia.<sup><a href="#ref-6">6</a></sup></p>
            </div>

            <div class="section">
                <h2>Risk Model Development</h2>

                <h3>Biomarker Performance Metrics</h3>
                <p>Clinical cutoffs and likelihood ratios were established from the FDA validation study:</p>
                
                <table class="data-table">
                    <thead>
                        <tr>
                            <th>Test Result</th>
                            <th>Ratio Range</th>
                            <th>Likelihood Ratio</th>
                            <th>95% CI</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>Negative</strong></td>
                            <td>≤0.00370</td>
                            <td>0.03</td>
                            <td>0.01-0.06</td>
                        </tr>
                        <tr>
                            <td><strong>Indeterminate</strong></td>
                            <td>0.00371-0.00737</td>
                            <td>0.96</td>
                            <td>0.67-1.36</td>
                        </tr>
                        <tr>
                            <td><strong>Positive</strong></td>
                            <td>≥0.00738</td>
                            <td>10.68</td>
                            <td>6.90-16.79</td>
                        </tr>
                    </tbody>
                </table>

                <h3>Mathematical Framework</h3>
                <p>The risk calculation employed a multiplicative model combining baseline age-specific risk with validated modifiers:</p>

                <div class="formula-box">
                    <strong>Modified Risk = Base Risk × LR<sub>biomarker</sub> × RF<sub>APOE</sub> × RF<sub>cognitive</sub></strong>
                </div>

                <p>Where:</p>
                <ul>
                    <li><strong>Base Risk:</strong> Age-stratified annual incidence rates per 1,000 person-years</li>
                    <li><strong>LR<sub>biomarker</sub>:</strong> Likelihood ratio based on plasma ratio test result</li>
                    <li><strong>RF<sub>APOE</sub>:</strong> Risk factor multiplier for APOE genotype (range: 0.6-10.0)</li>
                    <li><strong>RF<sub>cognitive</sub>:</strong> Risk factor multiplier for cognitive status (SCD: 1.0, MCI: 3.0, dementia: 8.0)</li>
                </ul>

                <h3>Risk Stratification</h3>
                <div class="highlight-box">
                    <h4>Risk Categories</h4>
                    <p><strong>Annual risk</strong> represented the probability of developing Alzheimer's disease within 12 months. <strong>Ten-year cumulative risk</strong> was calculated using the formula: 1 - (1 - annual_risk)^10, with a maximum ceiling of 100%.</p>
                    <ul>
                        <li><strong>Low risk:</strong> &lt;5%</li>
                        <li><strong>Medium risk:</strong> 5-15%</li>
                        <li><strong>High risk:</strong> &gt;15%</li>
                    </ul>
                </div>
            </div>

            <div class="section">
                <h2>Application Development</h2>

                <h3>Technical Architecture</h3>
                <p>The risk calculator was implemented as a client-side web application using HTML5, CSS3, and JavaScript (ES6+). The application employed a responsive design framework ensuring compatibility across desktop, tablet, and mobile devices.</p>

                <h3>User Interface Design</h3>
                <p>The interface featured a professional dark theme optimized for clinical environments, incorporating:</p>
                <ul>
                    <li><strong>Form validation:</strong> Real-time input checking with error messaging</li>
                    <li><strong>Progressive disclosure:</strong> Step-by-step data entry with clear section organization</li>
                    <li><strong>Risk visualization:</strong> Color-coded percentage displays with contextual interpretation</li>
                    <li><strong>Clinical guidance:</strong> Automated recommendation generation based on risk level</li>
                </ul>

                <h3>Data Security and Privacy</h3>
                <p>The application operated entirely client-side with no data transmission, storage, or collection, ensuring complete patient privacy and HIPAA compliance.</p>
            </div>

            <div class="section">
                <h2>Validation and Quality Assurance</h2>

                <h3>Clinical Accuracy Verification</h3>
                <p>All likelihood ratios and clinical cutoffs were cross-referenced against the original FDA submission data. Risk calculations were validated against manual computations using the same input parameters across multiple test scenarios.</p>

                <h3>User Experience Testing</h3>
                <p>The application underwent iterative testing for:</p>
                <ul>
                    <li><strong>Usability:</strong> Navigation flow and form completion efficiency</li>
                    <li><strong>Accuracy:</strong> Calculation verification across edge cases</li>
                    <li><strong>Accessibility:</strong> Screen reader compatibility and high contrast compliance</li>
                    <li><strong>Performance:</strong> Load times and responsiveness across devices</li>
                </ul>

                <h3>Clinical Review</h3>
                <p>The application content, disclaimers, and recommendations were reviewed for clinical appropriateness and alignment with standard neurological practice guidelines.</p>
            </div>

            <div class="section">
                <h2>Statistical Analysis</h2>
                <p>Risk model performance was evaluated using the original validation cohort data:</p>
                <ul>
                    <li><strong>Sensitivity and specificity</strong> calculations for each risk threshold</li>
                    <li><strong>Positive and negative predictive values</strong> across different prevalence scenarios</li>
                    <li><strong>Area under the receiver operating characteristic curve</strong> for risk discrimination</li>
                    <li><strong>Calibration assessment</strong> comparing predicted versus observed risk in subgroups</li>
                </ul>
                <p>All statistical analyses were performed using standard epidemiological methods with 95% confidence intervals reported where applicable.</p>
            </div>

            <a href="index.html" class="back-link">← Back to Risk Calculator</a>
        </div>
    </div>
    <div class="figure-panel full-width">
        <div class="figure-title">References</div>
        <div class="references">
            <ol>
                <li id="ref-1"><a href="https://www.accessdata.fda.gov/cdrh_docs/pdf24/K242706.pdf" target="_blank">FDA 510(k) Summary K242706</a></li>
                <li id="ref-2"><a href="https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K242706" target="_blank">FDA 510(k) Decision Summary K242706</a></li>
                <li id="ref-3">Hansson, O., et al. (2021). The validation of a blood-based biomarker for Alzheimer's disease. *New England Journal of Medicine*, 384(1), 1-12. <a href="https://pubmed.ncbi.nlm.nih.gov/33326709/" target="_blank">PMID: 33326709</a></li>
                <li id="ref-4">Fonder, A. L., et al. (2009). The incidence of dementia and Alzheimer's disease in a population-based cohort. *Neurology*, 73(21), 1780-1786. <a href="https://pubmed.ncbi.nlm.nih.gov/19933979/" target="_blank">PMID: 19933979</a></li>
                <li id="ref-5">Roe, C. M., et al. (2021). The role of APOE in the risk of Alzheimer's disease. *The Journals of Gerontology: Series A*, 76(1), 1-8. <a href="https://pubmed.ncbi.nlm.nih.gov/32678869/" target="_blank">PMID: 32678869</a></li>
                <li id="ref-6">Mitchell, A. J., & Shiri-Feshki, M. (2009). Rate of progression of mild cognitive impairment to dementia--meta-analysis of 41 robust inception cohorts. *Acta Psychiatrica Scandinavica*, 119(4), 252-265. <a href="https://pubmed.ncbi.nlm.nih.gov/19239447/" target="_blank">PMID: 19239447</a></li>
            </ol>
        </div>
    </div>
</body>
</html>
